Baseline characteristics and demographics
| Obinutuzumab (n=63) | Placebo (n=62) | |
| Age—years | 33.1±9.8 | 31.9±10.1 |
| Female—no (%) | 55 (87) | 51 (82) |
| Region—no (%) | ||
| Latin America and the Caribbean | 38 (60) | 47 (76) |
| Europe and Israel | 18 (29) | 7 (11) |
| USA | 7 (11) | 8 (13) |
| Hispanic or Latino ethnicity—no (%) | 42 (67) | 49 (79) |
| Race—no (%) | ||
| White | 28 (44) | 26 (42) |
| American Indian or Alaska Native | 11 (18) | 17 (27) |
| Black or African American | 6 (10) | 5 (8) |
| Asian | 3 (5) | 2 (3) |
| Other or unknown | 15 (24) | 12 (20) |
| Prior history of lupus nephritis—no (%) | 32 (51) | 32 (52) |
| Class IV lupus nephritis—no (%) | 40 (64) | 35 (57) |
| Concomitant class V lupus nephritis—no (%) | 20 (32) | 17 (27) |
| Serum creatinine—mg/dL | 0.87±0.34 | 0.80±0.33 |
| eGFR—mL/min/1.73 m2 | 102.0±30.6 | 102.1±32.9 |
| UPCR—g/g | 3.3±2.7 | 2.9±2.5 |
| Anti-dsDNA Ab >30 IU/mL—no (%) | 42 (67) | 46 (74) |
| C3 <90 mg/dL—no (%) | 43 (68) | 37 (60) |
| C4 <16 mg/dL—no (%) | 37 (59) | 44 (71) |
eGFR was calculated using the CKD-EPI creatinine equation.
Ab, antibody; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; ULN, upper limit of normal; UPCR, urine protein-to-creatinine ratio.